☆ 4.6 Letter

Reply: Potential role of Janus kinase inhibitors in COVID-19

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Volume 83, Issue 1, Pages E65-E65

Publisher

MOSBY-ELSEVIER

DOI: 10.1016/j.jaad.2020.04.098

Keywords

-

Categories

Dermatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Pharmacology & Pharmacy

Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19

Rajashri R. Naik, Ashok K. Shakya, Safwan M. Aladwan, Mohamed El-Tanani

Summary: The coronavirus is rapidly spreading worldwide, and viral management aims to disrupt the virus's life cycle, minimize lung damage, and alleviate severe symptoms. Various strategies have been implemented, including repurposing FDA-approved kinase inhibitors that have shown antiviral activity against multiple viruses, including those associated with COVID-19.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Cell Biology

Janus Kinase Signaling Pathway and Its Role in COVID-19 Inflammatory, Vascular, and Thrombotic Manifestations

Jonathan D. Ravid, Orly Leiva, Vipul C. Chitalia

Summary: SARS-CoV-2 infection leads to severe blood clot formation causing organ failure and death. Besides the cytokine storm, disruptions in platelets, endothelial cells, and the coagulation system play a crucial role in triggering systemic coagulopathy. Activated Janus kinase (JAK) signaling has been implicated in enhancing thrombotic processes and organ dysfunction. However, the potential therapeutic applications of JAK inhibitors for treating the inflammation-thrombosis phenotype in COVID-19 patients remain controversial.

CELLS (2022)

Add to Collection

Review Medicine, General & Internal

COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy

Mansoor Khaledi, Fatemeh Sameni, Sheida Yahyazade, Maedeh Radandish, Parviz Owlia, Nader Bagheri, Hamed Afkhami, Mohamad Mahjoor, Zahra Esmaelpour, Maryam Kohansal, Farzad Aghaei

Summary: Managing cytokine storm with JAK inhibitors could be an effective therapeutic strategy for treating severe COVID-19.

FRONTIERS IN MEDICINE (2022)

Add to Collection

Article Immunology

Oral Janus kinase inhibitors for treating hospitalized patients with COVID-19: An updated systematic review and meta- analysis of randomized controlled trials

Hung-Jen Tang, Teng-Song Weng, Yu -Hung Chen, Chien-Ming Chao

Summary: Oral JAKis can significantly reduce the risk of death among patients with COVID-19 and are well-tolerated by hospitalized patients.

JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2022)

Add to Collection

Review Pharmacology & Pharmacy

Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review

Nem Kumar Jain, Mukul Tailang, Hemant Kumar Jain, Balakumar Chandrasekaran, Biswa Mohan Sahoo, Anandhalakshmi Subramanian, Neelaveni Thangavel, Afaf Aldahish, Kumarappan Chidambaram, M. Alagusundaram, Santosh Kumar, Palani Selvam

Summary: Severe cases of COVID-19 are characterized by hyperinflammation and multiorgan failure. JAK-STAT signaling plays a role in the immunopathogenesis of COVID-19. Jakinibs, small molecules that target proinflammatory cytokines, are being investigated as potential treatments through clinical trials. Baricitinib is currently the only FDA-approved Jakinib for treating critical COVID-19 patients. Further studies are needed to understand the pathogenesis of COVID-19 and determine the optimal duration and combination therapy of Jakinibs. This review article provides important insights into the therapeutic implications of Jakinibs for COVID-19 treatment.

FRONTIERS IN PHARMACOLOGY (2023)

Add to Collection

Review Chemistry, Medicinal

Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues

Milo Gatti, Eleonora Turrini, Emanuel Raschi, Piero Sestili, Carmela Fimognari

Summary: There is a paradigm shift in drug development and clinical practice to combat COVID-19, with a focus on testing various pharmacological approaches like JAK inhibitors. These inhibitors possess key characteristics for successful repurposing, including convenient oral administration, favorable pharmacokinetic profiles, and dual anti-inflammatory and anti-viral effects. Efforts are also being made to address safety issues and expand usage in different patient populations.

PHARMACEUTICALS (2021)

Add to Collection

Review Immunology

Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus

Rongxiu Huo, Xinxiang Huang, Yang Yang, Jinying Lin

Summary: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by cytokine imbalance. Dysregulation of the JAK/STAT pathway plays a role in SLE pathogenesis. JAK inhibitors (JAKis) show promise in reducing corticosteroid and immunosuppressant use in SLE treatment. Clinical trials are ongoing, and JAKis may improve traditional treatment strategies for SLE.

JOURNAL OF INFLAMMATION RESEARCH (2023)

Add to Collection

Review Biochemistry & Molecular Biology

A guide to immunotherapy for COVID-19

Frank L. van de Veerdonk, Evangelos Giamarellos-Bourboulis, Peter Pickkers, Lennie Derde, Helen Leavis, Reinout van Crevel, Job J. Engel, W. Joost Wiersinga, Alexander P. J. Vlaar, Manu Shankar-Hari, Tom van der Poll, Marc Bonten, Derek C. Angus, Jos W. M. van der Meer, Mihai G. Netea

Summary: This review provides an overview of the evidence for immunotherapy strategies in COVID-19 patients, aiming to support clinical decision-making. Immune dysregulation plays a crucial role in the pathophysiology of COVID-19. Immune-based therapies, such as steroids or anti-cytokine therapies, have shown remarkable successes in treating COVID-19 patients. However, the complexity of disease phenotypes, patient heterogeneity, and variable quality of evidence from immunotherapy studies pose challenges to clinical decision-making. This review summarizes the evidence generated by major clinical trials of host-directed therapy and proposes an algorithm for guiding the use of immunotherapy strategies in the clinic, which can not only guide treatment decisions but also inform future trials investigating immunotherapy in severe infections.

NATURE MEDICINE (2022)

Add to Collection

Review Medicine, Research & Experimental

Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies

Gayathri Baburaj, Levin Thomas, Mahadev Rao

Summary: Lung cancer patients are at a higher risk of developing COVID-19 infection due to various risk factors, and caution is needed when selecting COVID-19 treatment drugs to avoid potential drug-drug interactions. Healthcare professionals should screen and identify potential adverse outcomes based on severity and documentation levels, and design appropriate preventive and management strategies.

ARCHIVES OF MEDICAL RESEARCH (2021)

Add to Collection

Review Chemistry, Medicinal

Interleukin Receptor Antagonists and Janus Kinase Inhibitors Repurposed for Treatment of COVID-19

Nitin Tandon, Vijay Luxami, Runjhun Tandon, Kamaldeep Paul

Summary: SARS-CoV-2 infection is the most contagious among the three coronavirus infections observed so far. It has severely impacted the global economy. Apart from vaccine development, repurposing of known safe and effective drugs is being explored to expedite the development of treatment.

MINI-REVIEWS IN MEDICINAL CHEMISTRY (2022)

Add to Collection

Review Immunology

The development of COVID-19 treatment

Yongliang Yuan, Baihai Jiao, Lili Qu, Duomeng Yang, Ruijuan Liu

Summary: The emergence of SARS-CoV-2 has led to the COVID-19 pandemic, which is the greatest global public health threat of this century. Recent studies have revealed many mysteries of SARS-CoV-2 pathogenesis, greatly enhancing the research on COVID-19 vaccines and therapies. However, significant questions remain regarding its treatment.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Review Medicine, General & Internal

The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-Analysis

Xueyang Zhang, Lianhan Shang, Guohui Fan, Xiaoying Gu, Jiuyang Xu, Yeming Wang, Lixue Huang, Bin Cao

Summary: This study conducted a systematic review and meta-analysis of JAK inhibitors for the treatment of COVID-19, and found that baricitinib may decrease mortality in hospitalized adult patients, especially for those who required supplemental oxygen or high-flow oxygen/non-invasive ventilation at baseline.

FRONTIERS IN MEDICINE (2022)

Add to Collection

Review Pharmacology & Pharmacy

The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19

Maria Sofia Basile, Eugenio Cavalli, James McCubrey, Jorge Hernandez-Bello, Jose Francisco Munoz-Valle, Paolo Fagone, Ferdinando Nicoletti

Summary: This review examines the involvement of the PI3K/Akt/mTOR pathway in COVID-19 and discusses the potential use of specific inhibitors of this pathway for treating the disease.

DRUG DISCOVERY TODAY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Lead optimization, pharmacophore development and scaffold design of protein kinase CK2 inhibitors as potential COVID-19 therapeutics

Siddharth Yadav, Shahzaib Ahamad, Dinesh Gupta, Puniti Mathur

Summary: The study aims to optimize Silmitasertib, develop pharmacophore models, and design unique scaffolds to modulate Protein kinase CK2 (CK2). Candidates structurally similar to Silmitasertib were identified through bioisostere replacement and docking approaches. Molecular dynamics simulations were used to evaluate the interaction and stability of promising candidates. Ligand-based and structure-based pharmacophore models were merged to build a hybrid hypothesis, which was validated and used to screen for favorable chemical features in kinase inhibitors. Novel scaffolds with the potential to modulate CK2 were identified through de-novo scaffold design.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2023)

Add to Collection

Review Immunology

Potential role of interferons in treating COVID-19 patients

Mohadeseh Haji Abdolvahab, Shima Moradi-kalbolandi, Mohammad Zarei, Deepanwita Bose, Keivan Majidzadeh-A, Leila Farahmand

Summary: COVID-19, caused by SARS-CoV-2, is a public health crisis originating from bats and transmitted to humans. The disease is mainly spread through respiratory means with an incubation period of 2-14 days, with symptoms including fever, sore throat, and cough. Treatment focuses on supportive care and interferons, with combination therapy potentially being more effective.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Add to Collection

Review Food Science & Technology

Very low-calorie ketogenic diet (VLCKD) in patients with psoriasis and obesity: an update for dermatologists and nutritionists

Luigi Barrea, Matteo Megna, Sara Cacciapuoti, Evelyn Frias-Toral, Gabriella Fabbrocini, Silvia Savastano, Annamaria Colao, Giovanna Muscogiuri

Summary: Psoriasis is a chronic immune-mediated skin disease influenced by genetic and lifestyle factors. Nutrition and obesity are significant contributors to its pathogenesis and severity. Certain diets with anti-inflammatory properties, such as the very-low-calorie ketogenic diet (VLCKD), may improve clinical severity by reducing weight and systemic inflammation.

CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION (2022)

Add to Collection

Article Dermatology

Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period

Matteo Megna, Eleonora Cinelli, Lucia Gallo, Elisa Camela, Angelo Ruggiero, Gabriella Fabbrocini

Summary: Efficacy and safety of risankizumab were confirmed in the treatment of psoriasis, with significant improvements observed in both PASI and BSA, even in a challenging population of patients with multiple treatment failures.

ARCHIVES OF DERMATOLOGICAL RESEARCH (2022)

Add to Collection

Letter Dermatology

Real-world experience versus clinical trials: pros and cons in psoriasis therapy evaluation

Eleonora Cinelli, Gabriella Fabbrocini, Matteo Megna

INTERNATIONAL JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study

A. Campanati, T. Bianchelli, R. Gesuita, C. Foti, G. Malara, G. Micali, P. Amerio, F. Rongioletti, M. Corazza, A. Patrizi, K. Peris, N. Pimpinelli, A. Parodi, M. C. Fargnoli, S. P. Cannavo, P. Pigatto, G. Pellacani, S. M. Ferrucci, G. Argenziano, F. Cusano, G. Fabbrocini, L. Stingeni, M. C. Potenza, M. Romanelli, L. Bianchi, A. Offidani, P. Romita, M. L. Musumeci, V. Piras, A. Borghi, C. Loi, N. Gori, F. Prigano, R. Gallo, M. Esposito, A. Campitello, L. Bolzano, S. Tavecchio, G. Calabrese, L. Di Costanzo, K. Hansel, N. Skroza, E. Tolino, G. Tonini, M. Talamonti

Summary: Adult atopic dermatitis is a systemic inflammatory disorder that is still not well understood in its relationship with immune-allergic and metabolic comorbidities. This study found a significant association between atopic conditions and moderate-to-severe AD in young adult patients, with oral corticosteroids and cyclosporine being the most commonly used treatments. Further long-term cohort studies are needed to evaluate the complex relationship between disease severity and metabolic comorbidities in adult AD patients.

ARCHIVES OF DERMATOLOGICAL RESEARCH (2022)

Add to Collection

Letter Dermatology

Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic

K. Hansel, C. Patruno, E. Antonelli, G. Dal Bello, M. Napolitano, G. Fabbrocini, T. Grieco, G. Pellacani, M. C. Fargnoli, M. Esposito, V. Piras, M. Zucca, G. Girolomoni, L. Stingeni

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)

Add to Collection

Letter Dermatology

Pityriasis rosea after Moderna mRNA-1273 vaccine: A case series

Fabrizio Martora, Gabriella Fabbrocini, Claudio Marasca

DERMATOLOGIC THERAPY (2022)

Add to Collection

Letter Dermatology

A case of erythrodermic psoriasis successfully treated with apremilast

Matteo Megna, Sonia Sofia Ocampo-Garza, Gabriella Fabbrocini, Eleonora Cinelli, Angelo Ruggiero, Elisa Camela

DERMATOLOGIC THERAPY (2022)

Add to Collection

Letter Dermatology

New-onset lichen planus arising after COVID-19 vaccination

Orlando Zagaria, Alessia Villani, Angelo Ruggiero, Luca Potestio, Gabriella Fabbrocini, Lucia Gallo

DERMATOLOGIC THERAPY (2022)

Add to Collection

Letter Dermatology

Generalized pustular psoriasis rapidly and successfully treated with ixekizumab in a Caucasian patient

Matteo Megna, Luisa Abategiovanni, Alberto Annunziata, Ginevra Torta, Tiziana Peduto, Gabriella Fabbrocini, Wanda Lauro

DERMATOLOGIC THERAPY (2022)

Add to Collection

Letter Dermatology

Acrodermatitis continua of Hallopeau successfully treated with ixekizumab: A case report

Teresa Battista, Gianluca Guerrasio, Gaia De Fata Salvatores, Tiziana Peduto, Gabriella Fabbrocini, Adriana Di Guida

DERMATOLOGIC THERAPY (2022)

Add to Collection

Letter Dermatology

Long-term results of teledermatology for acne patients during COVID-19 pandemic

Alessia Villani, Maria Carmela Annunziata, Matteo Megna, Massimiliano Scalvenzi, Gabriella Fabbrocini

JOURNAL OF COSMETIC DERMATOLOGY (2022)

Add to Collection

Letter Dermatology

Letter to the editor regarding the article Oguz Topal I, Kara Polat A, Zindanci I, et al. Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study. J Cosmet Dermatol. 2021;10.1111/jocd.14610

Luca Potestio, Elisa Camela, Andrea Tajani, Gabriella Fabbrocini, Matteo Megna

JOURNAL OF COSMETIC DERMATOLOGY (2022)

Add to Collection

Article Dermatology

An Unusual Case of Pemphigus Vulgaris

Laura Marano, Gabriella Fabbrocini, Giuseppe Monfrecola, Fabrizio Martora

Summary: This article presents a case report of a young woman initially diagnosed with seborrheic dermatitis but later confirmed to have pemphigus. The case highlights the importance of careful history-taking and clinical examination in diagnosing atypical manifestations of pemphigus, and emphasizes the need to avoid misdiagnosis.

SKIN APPENDAGE DISORDERS (2022)

Add to Collection

Article Dermatology

A Case of Pemphigus Vulgaris and Hidradenitis Suppurativa: May Systemic Steroids Be Considered in the Standard Management of Hidradenitis Suppurativa?

Fabrizio Martora, Lorenzo Martora, Gabriella Fabbrocini, Claudio Marasca

Summary: Recent studies have shown a correlation between pemphigus and hidradenitis suppurativa (HS). We present a case of a 58-year-old man with HS for about 30 years who was found to have pemphigus lesions during a checkup. There is limited data on the use of systemic corticosteroids for these two diseases, and our article aims to provide insight into the management and treatment of pemphigus and HS.

SKIN APPENDAGE DISORDERS (2022)

Add to Collection

Letter Dermatology

Sonidegib-induced muscle spasms in the treatment of basal cell carcinoma: Strategies to adopt

Alessia Villani, Gabriella Fabbrocini, Massimiliano Scalvenzi

DERMATOLOGIC THERAPY (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.